Dartmouth-Hitchcock logo
Back
 
Medicine Grand Rounds - CAR Talk – Chimeric Antigen Receptor (CAR) T-Cell Therapy Driving Progress in the Fight Against Cancer

Dr. Hill discusses this innovative and promising immunotherapeutic modality for a select subset of cancer patients with resistant disease. He outlines the specific clinical and laboratory steps that must be taken prior to initiating this treatment, as well as where the process may fail. He emphasizes vigilant monitoring post-infusion to watch for life threatening but treatable complications from cytokine release or neurotoxicity, and highlights the multi-disciplinary institutional commitment that is needed to successfully implement this high risk and complex treatment.

Activity Details

Start Date: March 22, 2019
End Date: March 22, 2021

You may claim CME credit for successful completion of this online course. In order to claim credit, you must follow these steps:

  1. Register for the learning activity by creating an account or logging in to your account.
  2. Click Continue to navigate to the Activity Material tab. Click View Presentation to view the recording.
  3. Return to this Activity page.
  4. Click Continue to navigate to the Evaluation tab; then click the Launch button to start the evaluation.
  5. Complete and Submit the evaluation and attestation form.

When the evaluation is submitted, you will be awarded credit. You may access your transcript for verification of participation at any time via Your Account. Need help? Visit the Support Page, send an Email, or call the Center for Learning and Professional Development at (603) 653-1234, Option 1.

Presenter
  • John M. Hill, MD
    Associate Professor of Medicine
    Geisel School of Medicine
    Director, Allogeneic Blood and Marrow Transplant Program
    Norris Cotton Cancer Center
    Dartmouth-Hitchcock Medical Center

    John M. Hill, Jr., MD received his undergraduate degree from Princeton University and his medical degree from the University Of Connecticut School Of Medicine.  He completed his Internal Medicine Residency at the National Naval Medical Center, Bethesda, Maryland and a Hematology/Oncology Fellowship training in the National Cancer Institute (NCI)/Navy combined program, including 6 months of clinical training in Bone Marrow Transplantation at the Fred Hutchinson Cancer Research Center in Seattle, WA. 
    Dr. Hill is particularly interested in the use of adoptive immunotherapy for the treatment of patients with hematologic malignancies and in novel approaches toward minimizing morbidity and mortality and optimizing functional status following allogeneic stem cell transplant.  This includes early detection and intervention for graft rejection, graft-versus-host disease, cardio-pulmonary sequelae and relapse of malignancy.
Learning Outcome

Participants will be able to discuss the rationale for and components of CAR T-Cell Therapy, as well as the potential mechanisms underlying failure. They will be able to summarize the two major complications of CAR T-Cell Therapy and their appropriate management.

Accreditation

Dartmouth-Hitchcock is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Dartmouth-Hitchcock designates this enduring material for a maximum of 1 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Requirements for Successful Completion

In order to receive credit for this Continuing Medical Education (CME) activity, you must:

  • View the entire presentation
  • Complete the online Attestation of Attendance & Evaluation Form (you must register to access).
Disclosure

In accordance with the disclosure policy of Dartmouth-Hitchcock/Geisel School of Medicine at Dartmouth as well as standards set forth by the Accreditation Council on Continuing Medical Education and the Nursing Continuing Education Council standards set forth by the American Nurses Credentialing Center Commission on Accreditation, continuing medical education and nursing education activity director(s), planning committee member(s), speaker(s), author(s) or anyone in a position to control the content have been asked to disclose any financial relationship* they have to a commercial interest (any entity producing, marketing, re-selling, or distributing health care goods or services consumed by, or used on patients). Such disclosure is not intended to suggest or condone bias in any presentation, but is elicited to provide participants with information that might be of potential importance to their evaluation of a given activity.

The following Activity Physician Director(s), planning committee member(s), speaker(s), author(s) or anyone in a position to control the content for CAR Talk – Chimeric Antigen Receptor (CAR) T-Cell Therapy Driving Progress in the Fight Against Cancer (Medicine Grand Rounds) have reported the following financial interest or relationship* with various companies/organizations. Dr. Hill reports no conflicts of interest. The Activity Director and Planning Committee member roles were resolved by altering the individual’s control over content about the products or services of the commercial interest by the Associate Dean for CME and the Department of Medicine Chair. All potential conflict(s) were resolved.


* Kelly Kieffer, MD ~ her spouse is a consultant for OcculoBio. 

* Richard I. Rothstein, MD ~ has research support from Baranova (research grant to Dartmouth-Hitchcock Medical Center) and has other financial interest from Allurion. 


Other planning committee member(s), speaker(s), activity director(s), author(s) or anyone in a position to control the content for this program report no financial interest or relationship* with any company(ies) or organizations whose product may be germane to the content of their presentations.

*A “financial interest or relationship" refers to an equity position, receipt of royalties, consultantship, funding by a research grant, receiving honoraria for educational services elsewhere, or to any other relationship to a company that provides sufficient reason for disclosure, in keeping with the spirit of the stated policy.

Provider Contact Information

Provider contact information for questions regarding accreditation of the activity:

Center for Learning and Professional Development
Dartmouth-Hitchcock Medical Center
clpd.support@hitchcock.org



Type:     Internet Activity (Enduring Material)
8 Registered Users

0